Trial Profile
A phase Ib safety and pharmacokinetic study of ARQ 501 [beta-lapachone] in combination with docetaxel in adult patients with locally advanced or metastatic carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Beta lapachone (Primary) ; Docetaxel
- Indications Cancer; Carcinoma
- Focus Adverse reactions
- Sponsors ArQule
- 20 Mar 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 07 Aug 2006 Status change
- 19 Sep 2005 New trial record.